- Home
- DAKT vs TECH Comparison
DAKT vs TECH Comparison
Compare DAKT & TECH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAKT
- TECH
- Stock Information
- Founded
- DAKT 1968
- TECH 1976
- Country
- DAKT United States
- TECH United States
- Employees
- DAKT N/A
- TECH N/A
- Industry
- DAKT Office Equipment/Supplies/Services
- TECH Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DAKT Industrials
- TECH Health Care
- Exchange
- DAKT Nasdaq
- TECH Nasdaq
- Market Cap
- DAKT N/A
- TECH 8.0B
- IPO Year
- DAKT 1994
- TECH 1989
- Fundamental
- Price
- DAKT $12.52
- TECH $50.25
- Analyst Decision
- DAKT Strong Buy
- TECH Buy
- Analyst Count
- DAKT 1
- TECH 8
- Target Price
- DAKT $26.00
- TECH $81.14
- AVG Volume (30 Days)
- DAKT 422.8K
- TECH 2.3M
- Earning Date
- DAKT 03-05-2025
- TECH 05-07-2025
- Dividend Yield
- DAKT N/A
- TECH 0.64%
- EPS Growth
- DAKT N/A
- TECH N/A
- EPS
- DAKT 0.04
- TECH 0.98
- Revenue
- DAKT $799,806,000.00
- TECH $1,196,016,000.00
- Revenue This Year
- DAKT N/A
- TECH $8.19
- Revenue Next Year
- DAKT $4.86
- TECH $8.61
- P/E Ratio
- DAKT $320.86
- TECH $51.28
- Revenue Growth
- DAKT N/A
- TECH 4.46
- 52 Week Low
- DAKT $9.22
- TECH $46.44
- 52 Week High
- DAKT $19.89
- TECH $85.57
- Technical
- Relative Strength Index (RSI)
- DAKT 49.39
- TECH 41.02
- Support Level
- DAKT $12.16
- TECH $49.15
- Resistance Level
- DAKT $12.80
- TECH $53.54
- Average True Range (ATR)
- DAKT 0.54
- TECH 2.94
- MACD
- DAKT 0.12
- TECH 0.37
- Stochastic Oscillator
- DAKT 75.14
- TECH 51.02
About TECH Bio-Techne Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.